Anti-Drug Antibodies in Patients with Fabry Disease Treated with Agalsidase-Alpha or -Beta: A Retrospective Italian Multicenter Study
Cells · 05.11.2026 · 15 (21) · 2015
DOI: 10.3390/cells15212015 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cells, online erschienen am 05.11.2026. Verfasst von Andrea Matucci und 28 weiteren Autor:innen. Beteiligte Einrichtung: Immunoallergology Unit, Careggi University Hospital, 50134 Florence, Italy. Hauptthemen laut MEDLINE: Fabry Disease, alpha-Galactosidase, Antibodies. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Universities and Research, Ministry of university and Research 2025.
Abstract (Originalsprache)
(1)
Background
Anti-drug antibodies (ADAs) may develop during enzyme replacement therapy (ERT) for Fabry disease and potentially affect biochemical response. Evidence have been derived mainly from males, while comparisons between agalsidase-alpha and agalsidase-beta remain limited by differences in ADA assays. The aim of the study is to evaluate ADA prevalence and titers in patients with Fabry disease treated with agalsidase-alpha or agalsidase-beta and to investigate associations with sex, GLA genotype, residual α-galactosidase A activity, and lyso-Gb3 levels. (2)
Methods
This multicenter observational study included 117 patients with Fabry disease receiving ERT (50 males, 67 females), treated with agalsidase-alpha (n = 52) or agalsidase-beta (n = 65). ADAs were measured using an in-house enzyme-linked immunosorbent assay, and lyso-Gb3 by liquid chromatography–tandem mass spectrometry. GLA variants were centrally classified as predicted null-type or predicted non-null-type on the basis of the variant class, and α-galactosidase A activity at diagnosis was normalized to the lower limit of the assay reference interval. Multivariable regression analysis identified factors associated with ADA positivity and lyso-Gb3 levels. (3)
Results
ADAs were detected in 55/117 patients. Positivity was more frequent in males than females, with no statistically significant difference between agalsidase-alpha and agalsidase-beta. Predicted null-type variants were associated with higher ADA positivity and titers, particularly in males. In multivariable models, male sex and predicted null-type variants independently predicted ADA positivity, whereas higher normalized α-galactosidase A activity was associated with lower odds. ADA positivity was not independently associated with lyso-Gb3. (4)
Conclusions
ADA detection was primarily associated with male sex and predicted null-type GLA variants; no statistically significant association with the agalsidase administered was found. The high prevalence of binding ADAs in females warrants confirmation using orthogonal and functional assays.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Immunoallergology Unit, Careggi University Hospital, 50134 Florence, Italy.
- Laboratory of Molecular Genetics of Neurometabolic Diseases, Neuroscience and Human Genetics Department, Meyer Children's Hospital IRCCS, 50134 Florence, Italy.
- Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence, 50139 Florence, Italy.
- Unit of Nephrology, Dialysis and Transplantation, AOM-IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.
- Department of Internal Medicine and Medical Specialties (DIMI), University of Genoa, 16132 Genova, Italy.
- Nephrology, Fondazione IRCCS San Gerardo dei Tintori, 20900 Monza, Italy.
ORCID-Profile: Pasquale Esposito, Federico Pieruzzi, Maurizio Pieroni, Elena Biagini, Raffaello Ditaranto, Maria Alessandra Schiavo, Cristina Sarti, Giulia Forni, Marina Rinaldi, Sandro Feriozzi, Matteo Accinno, Alessandra Vultaggio
Förderung
- Ministry of Universities and Research
- Ministry of university and Research 2025
Zitieren
APA
Matucci, A., Diomaiuti, M., Morrone, A., Esposito, P., Pieruzzi, F., Pieroni, M., Vivarelli, E., Biagini, E., Ditaranto, R., Schiavo, M. A., Cirami, C. L., Caroti, L., Dervishi, E., Romani, I., Sarti, C., Mangeri, M., Trezzi, B., Roggero, L., Sgattoni, C., …, & Vultaggio, A. (2026). Anti-Drug Antibodies in Patients with Fabry Disease Treated with Agalsidase-Alpha or -Beta: A Retrospective Italian Multicenter Study. Cells, 15(21), 2015. https://doi.org/10.3390/cells15212015
Vancouver
Matucci A, Diomaiuti M, Morrone A, Esposito P, Pieruzzi F, Pieroni M, et al. Anti-Drug Antibodies in Patients with Fabry Disease Treated with Agalsidase-Alpha or -Beta: A Retrospective Italian Multicenter Study. Cells. 2026;15(21):2015. doi:10.3390/cells15212015
BibTeX
@article{Matucci2026,
author = {Matucci, Andrea and Diomaiuti, Michael and Morrone, Amelia and Esposito, Pasquale and Pieruzzi, Federico and Pieroni, Maurizio and Vivarelli, Emanuele and Biagini, Elena and Ditaranto, Raffaello and Schiavo, Maria Alessandra and Cirami, Calogero Lino and Caroti, Leonardo and Dervishi, Egrina and Romani, Ilaria and Sarti, Cristina and Mangeri, Mario and Trezzi, Barbara and Roggero, Letizia and Sgattoni, Claudia and Gennarini, Alessia and la Marca, Giancarlo and Forni, Giulia and Mascia, Giacomo and Rinaldi, Marina and Del Franco, Annamaria and Argirò, Alessia and Feriozzi, Sandro and Accinno, Matteo and Vultaggio, Alessandra},
title = {Anti-Drug Antibodies in Patients with Fabry Disease Treated with Agalsidase-Alpha or -Beta: A Retrospective Italian Multicenter Study},
journal = {Cells},
year = {2026},
volume = {15},
number = {21},
pages = {2015},
doi = {10.3390/cells15212015}
}
EUVIMED